Consistent with these observations, recent studies have shown that treatment with the IL-6R inhibitor tocilizumab can inhibit biochemical markers of osteoclast-mediated bone destruction in RA patients [92]. This evidence concerns the gene IL6R and rheumatoid arthritis.